Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency ...
Peijia Medical Limited announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application fo...
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...
Ascentage Pharma Group International , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commerc...
Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system Aminex Therapeutics, Inc., a...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announced a collaboration with the Stanford Center for Definitive and C...
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro...
Cloud-based AI application for colorectal cancer prevention: Enhancing detection of clinically significant lesions without compromising safety and workfl...
Multi-study collaboration leverages SEQSTER's real world data (RWD) platform to support Praxis's portfolio of precision therapies for CNS disorders ...
Transaction expands MedImpact’s scale, expertise, and health solutions portfolio while maintaining Sav-Rx’s mission and service model ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, announced that the U.S. Food and Drug ...
Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...
SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The...
Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive the...
© 2026 Biopharma Boardroom. All Rights Reserved.
